Evidence map›Paper›PMID 34690535›Full record

ReviewJournal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology2021

Nanotechnology-based therapeutic formulations in the battle against animal coronaviruses: an update.

Saravanan Krishnan, Ashokkumar Thirunavukarasu, Niraj Kumar Jha, Rekha Gahtori, Ayush Singha Roy, Sunny Dholpuria, Kavindra Kumar Kesari, Sachin Kumar Singh, Kamal Dua, Piyush Kumar Gupta

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Saravanan KrishnanDhanvantari Nano Ayushadi Pvt Ltd, Chennai, 600017 India.
Ashokkumar ThirunavukarasuDhanvantari Nano Ayushadi Pvt Ltd, Chennai, 600017 India.
Niraj Kumar JhaDepartment of Biotechnology, School of Engineering and Technology (SET), Sharda University, Plot no. 32 - 34, Knowledge Park III, Greater Noida, 201310 Uttar Pradesh India.
Rekha GahtoriDepartment of Biotechnology, Sir J. C. Bose Technical Campus, Kumaun University, Nainital, 263136 Uttarakhand India.
Ayush Singha RoyDepartment of Biotechnology, Amity School of Biotechnology, Amity University, Mumbai-Pune Expressway, Mumbai, Maharashtra 410206 India.
Sunny DholpuriaDepartment of Life Sciences, J.C. Bose University of Science and Technology, YMCA, Faridabad, 121006 Haryana India.
Kavindra Kumar KesariDepartment of Applied Physics, School of Science, Aalto University, Espoo, Finland.
Sachin Kumar SinghSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab India.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007 Australia.
Piyush Kumar GuptaDepartment of Life Sciences, School of Basic Sciences and Research (SBSR), Sharda University, Plot no. 32 - 34, Knowledge Park III, Greater Noida, 201310 Uttar Pradesh India.ORCID 0000-0002-3346-910X
Dhanvantari Ayurveda College Hospital and Research Centre · INSharda University · INAalto University · FIJ.C. Bose University of Science & Technology, YMCA · INKumaun University · INLovely Professional University · INUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Outbreak of infectious diseases imposes a serious threat to human population and also causes a catastrophic impact on global economy. Animal coronaviruses remain as one of the intriguing problems, known to cause deadly viral diseases on economically important animal population, and also these infections may spread to other animals and humans. Through isolation of the infected animals from others and providing appropriate treatment using antiviral drugs, it is possible to prevent the virus transmission from animals to other species. In recent times, antiviral drug-resistant strains are being emerged as a deadly virus which are known to cause pandemic. To overcome this, nanoparticles-based formulations are developed as antiviral agent which attacks the animal coronaviruses at multiple sites in the virus replication cycle. Nanovaccines are also being formulated to protect the animals from coronaviruses. Nanoformulations contain particles of one or more dimensions in nano-scale (few nanometers to 1000 nm), which could be inorganic or organic in nature. This review presents the comprehensive outline of the nanotechnology-based therapeutics formulated against animal coronaviruses, which includes the nanoparticles-based antiviral formulations and nanoparticles-based adjuvant vaccines. The mechanism of action of these nanoparticles-based antivirals against animal coronavirus is also discussed using relevant examples. In addition, the scope of repurposing the existing nano-enabled antivirals and vaccines to combat the coronavirus infections in animals is elaborated.

Indexed as

AdjuvantAnimal coronavirusAntiviral agentNanoformulationNanoparticlesNanovaccine

Identifiers

PMID34690535
PMCPMC8520458
OpenAlexW3207772456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.